StatOrigin open statistical archive
Live Industries Statistics Regions Rankings Reports Compare Sources

C21 · Pharmaceuticals · 3 regions

Antibody-drug conjugate trial starts

Global: 349 in 2025, +23.8% on 2024.

  • 349 Latest · Global · 2025
  • +23.8% vs 2024
  • Annual Release cadence
  • 21 Records · 3 regions · 2020–2026

Verified 27 Sep 2026 · 1 publisher · Next period 2026

CSV JSON PNG Cite and reuse

Across regions

3 regions on one axis, spaced by time. Below it, the latest value of every region, ranked. Forecasts are dashed with hollow markers; the underlying values are one click away under the chart.

Fig 1 · C21 · 3 regions Annual

Antibody-drug conjugate trial starts by region

3 regions, 2020 to 2025

3 regions · 18 observations · 2020 to 2025
Antibody-drug conjugate trial starts by regionAntibody-drug conjugate trial starts by region. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 25 to 638. Latest values: Global 349 (2025); China 177 (2025); United States 144 (2025). 0 200 400 600 800 2020 2021 2022 2023 2024 2025 Global China United States
Antibody-drug conjugate trial starts by regionAntibody-drug conjugate trial starts by region. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 25 to 638. Latest values: Global 349 (2025); China 177 (2025); United States 144 (2025). 0 200 400 600 800 2020 2021 2022 2023 2024 2025 Global China United States
Antibody-drug conjugate trial starts by regionAntibody-drug conjugate trial starts by region. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 25 to 638. Latest values: Global 349 (2025); China 177 (2025); United States 144 (2025). 0 200 400 600 800 2020 2021 2022 2023 2024 2025 Global China United States
View the underlying data
Antibody-drug conjugate trial starts by region
Region Period Type Value
Global 2025 Actual 349
Global 2024 Actual 282
Global 2023 Actual 233
Global 2022 Actual 176
Global 2021 Actual 145
Global 2020 Actual 101
China 2025 Actual 177
China 2024 Actual 150
China 1 Jan 2023 to 27 Sep 2026 Actual 638
China 2022 Actual 69
China 2021 Actual 40
China 2020 Actual 25
United States 2025 Actual 144
United States 2024 Actual 105
United States 2023 Actual 94
United States 2022 Actual 96
United States 2021 Actual 94
United States 2020 Actual 73
Source: ClinicalTrials.gov · CC BY 4.0 · statorigin.org
Fig 2 · C21 · Latest by region

Antibody-drug conjugate trial starts by region

Latest value per region, 2025

3 entries
Antibody-drug conjugate trial starts by regionAntibody-drug conjugate trial starts by region. 3 categories, highest is Global at 349. United States China Global 144 177 349
Antibody-drug conjugate trial starts by regionAntibody-drug conjugate trial starts by region. 3 categories, highest is Global at 349. United States China Global 144 177 349
Antibody-drug conjugate trial starts by regionAntibody-drug conjugate trial starts by region. 3 categories, highest is Global at 349. United States China Global 144 177 349
View the underlying data
Antibody-drug conjugate trial starts by region
Category Source Type Value
Global ClinicalTrials.gov Actual 349
China ClinicalTrials.gov Actual 177
United States ClinicalTrials.gov Actual 144
Source: ClinicalTrials.gov · CC BY 4.0 · statorigin.org

Every record

21 records · 3 regions · 2020–2026. Each period links to its record: the value, the quote it was read from, and the document.

Antibody-drug conjugate trial starts: every record, grouped by region, newest first.
Period Value Source Type
Global 7 records
2025 349 ClinicalTrials.gov · 31 Dec 2025
2024 282 ClinicalTrials.gov · 31 Dec 2024
1 Jan 2023 to 27 Sep 2026 1,225 ClinicalTrials.gov · 27 Sep 2026
2023 233 ClinicalTrials.gov · 31 Dec 2023
2022 176 ClinicalTrials.gov · 31 Dec 2022
2021 145 ClinicalTrials.gov · 31 Dec 2021
2020 101 ClinicalTrials.gov · 31 Dec 2020
China 7 records
2025 177 ClinicalTrials.gov · 31 Dec 2025
2024 150 ClinicalTrials.gov · 31 Dec 2024
1 Jan 2023 to 27 Sep 2026 638 ClinicalTrials.gov · 27 Sep 2026
2023 120 ClinicalTrials.gov · 31 Dec 2023
2022 69 ClinicalTrials.gov · 31 Dec 2022
2021 40 ClinicalTrials.gov · 31 Dec 2021
2020 25 ClinicalTrials.gov · 31 Dec 2020
United States 7 records
2025 144 ClinicalTrials.gov · 31 Dec 2025
2024 105 ClinicalTrials.gov · 31 Dec 2024
1 Jan 2023 to 27 Sep 2026 428 ClinicalTrials.gov · 27 Sep 2026
2023 94 ClinicalTrials.gov · 31 Dec 2023
2022 96 ClinicalTrials.gov · 31 Dec 2022
2021 94 ClinicalTrials.gov · 31 Dec 2021
2020 73 ClinicalTrials.gov · 31 Dec 2020

Download this data

PNG chart SVG chart CSV data JSON series API

Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: ClinicalTrials.gov. Licence: CC BY 4.0.

Embed this chart

Free to embed anywhere, including commercially. The attribution bar is part of the chart.

<iframe src="https://statorigin.org/embed/pharmaceuticals--ctgov-adc-trial-starts--regions" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Antibody-drug conjugate trial starts by region" loading="lazy"></iframe>
<p><a href="https://statorigin.org/indicators/ctgov-adc-trial-starts">Antibody-drug conjugate trial starts by region</a>, data from StatOrigin, CC BY 4.0</p>
Preview embed

Use and publication rights

  • View, cite and link: free

    Quote any number, cite this page or a single record, and link to it anywhere.

  • Copy, chart and republish: free with attribution

    The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (ClinicalTrials.gov); the chart files already carry that line.

  • The source documents: the publisher's terms

    Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.

How this measure is built

Definition
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
Measure
One slice of Clinical trial starts ( basis: clinicaltrials gov registry, counting rule: by start date, form: count, segment: adc ) . Total number of clinical trials initiated during a given period. Region and period are columns on every record, not slices.
Limitations
Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
Verification
Each value, unit, period and place was checked against its quote before publication. See the methodology and the corrections process.

Sources · 21 documents

Document Publisher Published Data points
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1

Other slices of clinical trial starts

Frequently asked questions

What is the latest antibody-drug conjugate trial starts?

Global: 349 in 2025, +23.8% on 2024.

Where does this data come from?

From 21 documents published by ClinicalTrials.gov. Every figure on this page links to its record, which quotes the sentence or table row the number was read from.

How often is it updated?

Annual. The newest published period is 2025; the next release should cover 2026. A new figure appears here once the publisher releases it and it passes verification.

Can I use this data?

Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.

Cite this page

Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.

StatOrigin. (2026). Antibody-drug conjugate trial starts [Data set]. Retrieved September 29, 2026, from https://statorigin.org/indicators/ctgov-adc-trial-starts

"Antibody-drug conjugate trial starts." StatOrigin, 2026, https://statorigin.org/indicators/ctgov-adc-trial-starts. Accessed 29 Sep. 2026.

StatOrigin. "Antibody-drug conjugate trial starts." Data set, 2026. Accessed September 29, 2026. https://statorigin.org/indicators/ctgov-adc-trial-starts.

@misc{statorigin_ctgov_adc_trial_starts_2026, title = {Antibody-drug conjugate trial starts}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/ctgov-adc-trial-starts}, note = {Data set. Accessed 2026-09-29} }